The angiotensin-converting enzyme inhibitor ramipril also reduces ventricular and vascular remodelling. The open-label study observed 75 treatment-naïve, moderately or severely hypertensive (systolic blood pressure 160 -190 mmHg, diastolic blood pressure 90 -110 mmHg) patients (age range, 42 -58 years) treated with once-daily telmisartan 40 mg force-titrated to 80 mg after 1 month (n = 25), once-daily ramipril 2.5 mg force-titrated to 5 mg after 1 month (n = 25), or once-daily telmisartan 40 mg plus ramipril 2.5 mg (n = 25); the total duration of treatment was 6 months. At baseline, blood pressure, left ventricular mass index (LVMI), carotid intima-media thickness (IMT) and carotid cross-sectional intima-media area (CSA) were measured. Measurements were repeated 1, 3 and 6 months after initiation of treatment. After 6 months, comparable blood pressure reductions were achieved with the three treatments. Reductions in LVMI after 6 months' treatment were 11.4%, 9.9% and 15.6% with telmisartan, ramipril, and telmisartan plus ramipril, respectively. Respective reductions in IMT were 14.6%, 12.0% and 18.2%, and for CSA were 7.8%, 4.3% and 11.5%. In conclusion, treatment with telmisartan or ramipril for 6 months resulted in regression of LVH and vascular remodelling. When a combination of telmisartan and ramipril was administered, additional regression and remodelling occurred.
Introduction
Ageing and hypertension are characterized by increased incidences of coronary and cerebrovascular disease. 1 Most of these cardiovascular complications, such as stroke and myocardial infarction, are the result of changes in vascular structure and function. 2 An early consequence of hypertension is left ventricular hypertrophy (LVH), as a result of changing mechanical and/or biochemical stimuli. 3 The myocardium is composed of cardiac myocytes and interstitial cells (vascular endothelial cells, vascular smooth muscle cells, fibroblasts and macrophages). The endothelial cells within the vasculature secrete mediators that influence vascular haemodynamics in the physiological state and contribute to the regulation of blood pressure and blood flow: prostacyclin and nitric oxide are vasodilatory, and plateletactivating factor and endothelin act as vasoconstrictors. 4 Angiotensin II plays a pivotal role in LVH and vascular remodelling, and acts throughout the cardiovascular continuum to increase morbidity and mortality. 5 Suppression of angiotensin II produced by the renin -angiotensin system (RAS), using an angiotensin-converting enzyme (ACE) inhibitor, results in a reduction of thrombus formation and surface expression of platelet glycoprotein IIb/IIIa following myocardial infarctions. 6 Studies have also demonstrated the effectiveness of ACE inhibitors in the prevention and regression of LVH. 7 The RAS has been classically viewed as an endocrine system, comprising organs that secrete a precursor and various regulatory enzymes into the circulation. The final product, angiotensin II, is formed when circulating ACE cleaves angiotensin I. Angiotensin II then exerts its influences on distant targets that have the necessary receptors. More recently, it has become apparent that some organs, such as the heart, synthesize all the necessary components for a local RAS. 4 The identification of RAS components and angiotensin II receptors in cardiac tissue suggests the existence of an autocrine/paracrine system that has effects independent of angiotensin II derived from the circulatory system.
The angiotensin type 1 (AT 1 ) receptors present in various peripheral tissues and organs mediate most of the classic actions of angiotensin II, including its trophic and hyperplastic cardiovascular effects. 8 In contrast, AT 2 receptors have some antagonistic properties. Angiotensin II acting via the AT 1 receptor has been demonstrated, in addition to classic pressor, hydroelectrolytic, dypsogenic and vasopressin-and aldosteronereleasing properties, to bring about remodelling, oxidative stress, inflammation and atherogenesis in the heart. 7 In hypertension, the stretching of the myocardial fibres activates the enzymatic cascade that generates angiotensin II and the gene expression of transmembrane AT 1 receptors. 9 Angiotensin II acts via the AT 1 receptor to produce growth factors (basic fibroblast growth factor, platelet-derived growth factor, transforming growth factor-β) and extracellular matrix proteins (collagen, fibronectin, tenascin) that affect vascular and cardiac hypertrophy and remodelling. 10 Locally synthesized and circulating angiotensin II induces changes in volume, myocardial compliance and contractility, following the activation of the growth factors of myocytes and fibroblasts, resulting in heart cell proliferation, hypertrophy and hyperplasia. 11 In the Heart Outcomes Prevention Evaluation (HOPE) study, it was demonstrated that the ACE inhibitor ramipril significantly reduced incidences of death, myocardial infarction and stroke in a 40A J Petrovic, D Petrovic, N Vukovic et al. Telmisartan and/or ramipril in ventricular/vascular remodelling broad range of patients at high risk of cardiovascular events. 12 In a substudy of HOPE, patients were evaluated for LVH electrocardiographically. 13 Over the 4.5 years of the study, the incidence of regression/ prevention of LVH was statistically significantly higher in the patients treated with ramipril compared with that in those receiving placebo. 13 This effect of ramipril was independent of any blood pressure reduction, and was associated with a reduced risk of death, myocardial infarction, stroke and congestive heart failure.
Animal models have already demonstrated the beneficial effects of the angiotensin II receptor blocker (ARB) telmisartan on cardiac remodelling. Telmisartan treatment resulted in a statistically significantly greater reduction in the weight of the left ventricle compared with placebo in diabetic, spontaneously hypertensive rats and in stroke-prone, spontaneously hypertensive rats. 14, 15 Furthermore, a reduction in cardiac hypertrophy, detected histologically by a reduction in the diameter of hypertrophied myocardial muscle bundles, was observed in transgenic rats at a dose of telmisartan that had only marginal effects on blood pressure. 16 The efficacy of telmisartan has also been demonstrated clinically, with it producing a greater reduction in left ventricular mass index (LVMI) than the βblocker carvedilol. 17 This finding suggests that AT 1 receptor blockade provides an important mechanism, beyond that of lowering blood pressure, in the regression of cardiac hypertrophy in hypertensive patients.
In the present study, the effect of ramipril was compared with that of telmisartan on blood pressure. Target-organ damage is an important consequence of hypertension; thus, the regression of LVH or vascular remodelling, which are early events within 
TREATMENT
In this open-label study, patients were randomized to either once-daily ramipril 2.5 mg for the first month with forced titration to once-daily ramipril 5 mg given for 5 months, or to once-daily telmisartan 40 mg for the first month followed by forced titration to telmisartan 80 mg given for 5 months. Patients were instructed to take their medication between 12:00 and 14:00. In patients who did not achieve adequate blood pressure control, defined as a decrease of ≤ 7.5% in SBP and/or ≤ 5% in DBP after receipt of monotherapy for 2 weeks, a combination of ramipril 2.5 mg plus telmisartan 40 mg was administered once daily for 5.5 months. All patients also received advice on diet, exercise, alcohol intake and stopping smoking.
TREATMENT EVALUATION

Blood pressure
Trough supine blood pressure was measured, as at baseline and after 1, 3 and 6 months of treatment.
LVMI
All subjects underwent M-mode, twodimensional and Doppler echocardiography at baseline and after 1, 3 and 6 months of treatment performed by a research technician using the Acuson 128 XP/10 system equipped with 2.5-MHz transducers. Tracings were obtained with the patient in a partial left decubitus position. Scans were recorded on videotape for offline analysis. Echocardiographic readings were performed in random order by an evaluator, who had no knowledge of the patient's treatment, blood pressure or other clinical data. Only frames with optimal visualization of cardiac structures were considered for evaluation. Mean values were computed from a minimum of five measurements for each parameter. The reproducibility of measurements was optimized by having the same experienced technician perform all studies in a dimly lit and quiet room. M-mode recordings were obtained at or just below the tip of the mitral valve. Interventricular septal thickness, posterior wall thickness and left ventricular internal dimension were determined at end-diastole and end-systole as recommended by the American Society of Echocardiography. 18 The LVMI (g/m 2 ) was calculated using Devereux's formula: 19 -21 
where A 1 = left ventricular epicardial shortaxis area at the level of the papillary muscle tips at end-diastole; A 2 = left ventricular endocardial short-axis cavity area at the level of the papillary muscle tips at enddiastole; L = left ventricular long-axis length at end-diastole (obtained with apical fourchamber or two-chamber views); and t = myocardial wall thickness at end-diastole.
Carotid intima-media thickness
Imaging of both carotid arteries was performed at baseline and after 1, 3 and 6 months' treatment using high-resolution ultrasound (Acuson 128 XP/10 system) with a 7.0-MHz imaging transducer. With subjects supine, with slight hyperextension of the neck, the common carotid artery, carotid bulb and bifurcation were identified. The distal 1.0 cm of the near and far walls of the common carotid arteries was scanned; the crest at the origin of the bifurcation was used as an anatomical landmark to identify this segment. Anterior, lateral and posterior scanning angles were used to identify the greatest IMT in each wall. Scans were recorded on videotape for off-line analysis. Readers selected the frame that contained the thickest IMT for each of the four carotid 43A J Petrovic, D Petrovic, N Vukovic et al. Telmisartan and/or ramipril in ventricular/vascular remodelling walls, and the mean of the four maximal IMTs was calculated. The common carotid lumen diameter was measured as the distance between the leading edge of the echo produced by the intima-lumen interface of the near wall and the leading edge of the echo produced by the lumenintima interface of the far wall. 22 -24 
Cross-sectional intima-media area
The CSA was calculated using the following formula:
STATISTICAL ANALYSIS
All statistical analyses were performed with Epi Info™ Version 5.0 (Centers for Disease Control and Prevention, Atlanta). Continuous variables were expressed as mean ± SE. Student's t-test was used to test for significance in small, tied samples. Analysis of variance was performed to compare parameters among patients in the different treatment groups in homogeneous, independent samples. A P-value of < 0.05 was considered statistically significant.
Results
PATIENT CHARACTERISTICS
Clinical and biochemical characteristics of the 75 patients in the three treatment groups at baseline are summarized in Table 1 . All patients were moderately or severely hypertensive. In addition, all patients displayed LVH at baseline, defined as an LVMI of > 100 g/m 2 in women and > 120 g/m 2 in men.
BLOOD PRESSURE
After 6 months' treatment, SBP was reduced from baseline in all treatment groups (Fig. 1a ). Reductions in SBP compared with baseline in all three treatment groups were significant after 3 months (P < 0.03) and 6 months (P < 0.01), but differences between treatments were not significant. DBP was also significantly reduced (P < 0.01) in all three treatment groups after 6 months' therapy compared with baseline ( Fig. 1b ).
LVMI
After 6 months' treatment, a reduction in LVMI was observed in all three treatment groups compared with baseline (P < 0.05, for all) (Fig. 2) ; percentage reductions with telmisartan, ramipril, and telmisartan plus ramipril were 11.4%, 9.9% and 15.6%, respectively. Telmisartan monotherapy (P = 0.002) and telmisartan plus ramipril combination therapy (P = 0.00001) brought about significantly greater reductions in LVMI than ramipril monotherapy after 6 months' treatment. The superiority of telmisartan plus ramipril compared with ramipril alone in reducing LVMI was also apparent after 3 months (P = 0.038). Similarly, telmisartan plus ramipril produced a statistically greater reduction in LVMI compared with telmisartan monotherapy after 6 months' treatment (P = 0.032).
CAROTID INTIMA-MEDIA THICKNESS
Common carotid IMT measurements were performed in all 75 subjects. There was a significant (P < 0.05) reduction in IMT after 6 months in all three treatment groups compared with baseline, with telmisartan producing a greater reduction (P = 0.0015) than ramipril (Fig. 3 ). Percentage reductions with telmisartan, ramipril, and telmisartan plus ramipril were 14.6%, 12.0% and 18.2%, respectively. The reductions in IMT achieved with a combination of telmisartan plus ramipril after 6 months were significantly greater than those achieved with ramipril monotherapy after 6 months (P < 0.00014). Also, significantly greater reductions in IMT 44A J Petrovic, D Petrovic, N Vukovic et al. were detected in patients treated with a combination of ramipril plus telmisartan than in those treated with telmisartan monotherapy after 3 months (P = 0.02) and 6 months (P = 0.00036).
Telmisartan and/or ramipril in ventricular/vascular remodelling
CROSS-SECTIONAL INTIMA-MEDIA AREA
Statistically significant reductions in CSA compared with baseline were noted at the end of treatment in patients treated with 46A J Petrovic, D Petrovic, N Vukovic et al. Telmisartan and/or ramipril in ventricular/vascular remodelling telmisartan or telmisartan plus ramipril (P < 0.05) (Fig. 4) . Percentage reductions were 7.8%, 4.3% and 11.5% with telmisartan, ramipril, and telmisartan plus ramipril, respectively. The reduction brought about by telmisartan plus ramipril was significantly greater than that due to telmisartan monotherapy (P < 0.01). Compared with the effect of ramipril, the effect of telmisartan plus ramipril was statistically superior after 3 months (P = 0.0032) and 6 months (P = 0.0001). Telmisartan produced a greater 
Discussion
In our study, after 6 months of once-daily therapy, telmisartan 80 mg, ramipril 5 mg, and telmisartan 40 mg plus ramipril 2.5 mg all brought about significant reductions in SBP and DBP, but the decreases did not vary significantly between treatments. Despite the similar blood pressure lowering abilities of the three treatments, distinctions were identified when changes in LVMI were examined. When administered for 6 months, both telmisartan and telmisartan plus ramipril were more effective than a comparable duration of ramipril monotherapy in reducing the LVMI. The importance of the tissue angiotensin II receptors in the proliferative process in endothelial and vascular smooth muscle cells is well established. 25 Thus, the direct targeting of these receptors may have beneficial effects in the prevention of hypertension and LVH. Angiotensin II has been demonstrated to promote collagen production by myocardial fibroblasts. 26 The effect of telmisartan on the collagen production, which contributes to LVH, has been demonstrated in a pre-clinical model, which showed that pre-treatment of cultured rat fibroblasts with telmisartan, but not with the AT 2 receptor blocker P186, resulted in a reduction of angiotensin IIinduced collagen secretion and production. 27 This suggests that the effect of angiotensin II on myocardial fibrosis is mediated by the AT 1 receptor. Similarly, telmisartan has been demonstrated to prevent cardiac hypertrophy independently of its haemodynamic actions. 16 Selective blockade of AT 1 receptors within the heart not only inhibits detrimental effects in cardiac tissue, but also may result in available angiotensin II stimulating the AT 2 receptor with the possible inhibition of pathological growth. Our study, therefore, suggests the beneficial effect of telmisartan on ventricular remodelling in humans in comparison with ramipril. Further benefit was achieved by the dual blockade of the RAS Thickening of the carotid intima-media is a reliable and precise surrogate indicator of vascular smooth muscle cell hypertrophy and proliferative processes of vascular structure (i.e. vascular remodelling). 28 The carotid intima-media, examined by ultrasound, is thickened in hypertensive patients, 29 and the prevalence of IMT is more evident in subjects with LVH. 28 In our study, 6 months' treatment with agents targeting the RAS brought about significant reductions in IMT, although the effect of telmisartan was significantly superior to that of ramipril. The use of two agents to provide dual blockade of the RAS provided greater reduction of the IMT at 6 months, and significant improvement was noted after only 3 months' treatment. Similarly, treatment with a combination of telmisartan and ramipril resulted in a greater reduction in CSA than monotherapy, with a significant effect being observed after 3 months. These observations endorse the advantage of more comprehensive targeting of the RAS. The long-term cardiovascular benefits of administering a combination of ramipril and telmisartan in high-risk patients is being evaluated in the large-scale outcomes trial -ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial ONTARGET). 30 The results of our study demonstrate the beneficial effects of blocking the tissue AT 1 receptors by the use of the ARB telmisartan, as opposed to reducing circulating levels of angiotensin II by use of the ACE inhibitor ramipril. We conclude that the benefits in terms of regression of left ventricular and vascular remodelling using telmisartan are a consequence of the anti-proliferative effect of the ARB in addition to its anti-hypertensive efficacy. Further benefit was gained by targeting systemic and local production of angiotensin II by using a combination of telmisartan plus ramipril.
